{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T09:13:00Z","timestamp":1778058780395,"version":"3.51.4"},"reference-count":222,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100021671","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA229164"],"award-info":[{"award-number":["R01-CA229164"]}],"id":[{"id":"10.13039\/501100021671","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Neurological Diseases and Stroke","award":["R01-NS131106"],"award-info":[{"award-number":["R01-NS131106"]}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0055"],"award-info":[{"award-number":["W81XWH-21-1-0055"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eric Muirhead Chair of Excellence"},{"name":"UTHSC Center for Cancer Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancers of the breast and prostate are one of the leading causes of cancer deaths in women and men, respectively. Although several treatment options have been developed to transform these cancers into manageable chronic diseases, they still contribute to over 70 000 deaths each year in the United States. Though majority of these cancers belong to slow growing differentiated subtypes, the cancers evolve over time due to treatment-related pressure into aggressive treatment-resistant types. A mechanism attributed to the transformation of hormonal and other cancers into aggressive treatment-refractory cancers is \u201clineage plasticity,\u201d a term used to describe a switch in the cell type or lineage. Evolving evidences suggest that the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway plays a key role in driving lineage plasticity. This review discusses the role of JAK-STAT signaling pathway in hormonal cancers\u2019 evolution into aggressive cancers and in treatment resistance, with focus on treatment-induced lineage plasticity.<\/jats:p>","DOI":"10.1210\/endocr\/bqag035","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:47:20Z","timestamp":1774702040000},"source":"Crossref","is-referenced-by-count":0,"title":["Role of Janus kinase-signal transducer and activator of transcription signaling pathway in hormonal cancer therapeutic resistance and lineage plasticity"],"prefix":"10.1210","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5066-8119","authenticated-orcid":false,"given":"Wendy","family":"Effah","sequence":"first","affiliation":[{"name":"Department of Medicine, College of Medicine, University of Tennessee Health Science Center , Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8596-6263","authenticated-orcid":false,"given":"Marjana","family":"Khalil","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, University of Tennessee Health Science Center , Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6104-3600","authenticated-orcid":false,"given":"Sanskrita","family":"Sukla","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, University of Tennessee Health Science Center , Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5607-7443","authenticated-orcid":false,"given":"Chenhao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center , Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suriyan","family":"Ponnusamy","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, University of Tennessee Health Science Center , Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2809-1234","authenticated-orcid":false,"given":"Lawrence M","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Department of Pathology, College of Medicine, University of Tennessee Health Science Center , Memphis, TN, USA"},{"name":"UTHSC Center for Cancer Research, University of Tennessee Health Science Center , Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7627-8493","authenticated-orcid":false,"given":"Hyo Young","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center , Memphis, TN, USA"},{"name":"UTHSC Center for Cancer Research, University of Tennessee Health Science Center , Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5490-0790","authenticated-orcid":false,"given":"Ramesh","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, University of Tennessee Health Science Center , Memphis, TN, USA"},{"name":"UTHSC Center for Cancer Research, University of Tennessee Health Science Center , Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"47","key":"2026050604165853000_bqag035-B1","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1038\/sj.onc.1206937","article-title":"Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling","volume":"22","author":"Clarke","year":"2003","journal-title":"Oncogene"},{"issue":"1","key":"2026050604165853000_bqag035-B2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/35094009","article-title":"The development of androgen-independent prostate cancer","volume":"1","author":"Feldman","year":"2001","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2026050604165853000_bqag035-B3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1477-7827-1-73","article-title":"Estrogen, progesterone and epithelial ovarian cancer","volume":"1","author":"Ho","year":"2003","journal-title":"Reprod Biol Endocrinol"},{"issue":"18","key":"2026050604165853000_bqag035-B4","first-page":"6768","article-title":"Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells","volume":"61","author":"Syed","year":"2001","journal-title":"Cancer Res"},{"issue":"2-3","key":"2026050604165853000_bqag035-B5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12672-019-0358-9","article-title":"Estrogen signaling in endometrial cancer: a key oncogenic pathway with several open questions","volume":"10","author":"Rodriguez","year":"2019","journal-title":"Horm Cancer"},{"issue":"19","key":"2026050604165853000_bqag035-B6","doi-asserted-by":"crossref","first-page":"11952","DOI":"10.3390\/ijms231911952","article-title":"The roles of androgens in humans: biology, metabolic regulation and health","volume":"23","author":"Alemany","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2026050604165853000_bqag035-B7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.molmed.2012.12.007","article-title":"Estrogen synthesis and signaling pathways during aging: from periphery to brain","volume":"19","author":"Cui","year":"2013","journal-title":"Trends Mol Med"},{"issue":"7","key":"2026050604165853000_bqag035-B8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.19236","article-title":"Exogenous hormones, tumor intrinsic subtypes, and breast cancer","volume":"8","author":"Le Cornet","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2026050604165853000_bqag035-B9","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2026050604165853000_bqag035-B10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0002-9440(10)61676-8","article-title":"Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma","volume":"159","author":"Leav","year":"2001","journal-title":"Am J Pathol"},{"issue":"5","key":"2026050604165853000_bqag035-B11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrc801","article-title":"A history of prostate cancer treatment","volume":"2","author":"Denmeade","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2026050604165853000_bqag035-B12","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2020.151659","article-title":"Correlation of expression of hormone and HER2 receptors with various clinico-pathological prognostic parameters and with each other in malignant breast lesion","volume":"50","author":"Mohanty","year":"2021","journal-title":"Ann Diagn Pathol"},{"issue":"4B","key":"2026050604165853000_bqag035-B13","first-page":"749","article-title":"Differentiated DNA analysis in relation to steroid receptor status, grading, and staging in human breast cancer","volume":"7","author":"Meckenstock","year":"1987","journal-title":"Anticancer Res"},{"issue":"1","key":"2026050604165853000_bqag035-B14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4274\/ejbh.galenos.2023.2023-6-3","article-title":"The clinical and pathological characteristics that differentiate cases with \u201clow estrogen receptor expression\u201d from triple-negative breast cancer","volume":"20","author":"Karaali","year":"2024","journal-title":"Eur J Breast Health"},{"issue":"2","key":"2026050604165853000_bqag035-B15","doi-asserted-by":"crossref","first-page":"592","DOI":"10.18632\/oncotarget.2831","article-title":"Androgen receptors beyond prostate cancer: an old marker as a new target","volume":"6","author":"Munoz","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"2026050604165853000_bqag035-B16","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41388-020-01598-0","article-title":"Loss and revival of androgen receptor signaling in advanced prostate cancer","volume":"40","author":"Formaggio","year":"2021","journal-title":"Oncogene"},{"key":"2026050604165853000_bqag035-B17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-981-96-2763-9_8","volume-title":"Cell Signaling Pathways and Their Therapeutic Implication in Cancers","author":"Rehman","year":"2025"},{"key":"2026050604165853000_bqag035-B18","first-page":"325","article-title":"Cell identification and cell lineage analysis","volume":"106","author":"Giurumescu","year":"2011","journal-title":"Methods Cell Biol"},{"issue":"1","key":"2026050604165853000_bqag035-B19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/genetics\/77.1.71","article-title":"The genetics of Caenorhabditis elegans","volume":"77","author":"Brenner","year":"1974","journal-title":"Genetics"},{"issue":"2","key":"2026050604165853000_bqag035-B20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/genetics\/96.2.435","article-title":"Isolation and genetic characterization of cell-lineage mutants of the nematode Caenorhabditis elegans","volume":"96","author":"Horvitz","year":"1980","journal-title":"Genetics"},{"key":"2026050604165853000_bqag035-B21","volume-title":"The Strategy of the Genes","author":"Waddington","year":"1957"},{"issue":"7273","key":"2026050604165853000_bqag035-B22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nature08533","article-title":"Forcing cells to change lineages","volume":"462","author":"Graf","year":"2009","journal-title":"Nature"},{"issue":"5","key":"2026050604165853000_bqag035-B23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"issue":"1","key":"2026050604165853000_bqag035-B24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev-cancerbio-030617-050224","article-title":"Lineage plasticity in cancer progression and treatment","volume":"2","author":"Le Magnen","year":"2018","journal-title":"Annu Rev Cancer Biol"},{"issue":"1","key":"2026050604165853000_bqag035-B25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"Emt: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"issue":"4","key":"2026050604165853000_bqag035-B26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc2620","article-title":"Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits","volume":"9","author":"Polyak","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2026050604165853000_bqag035-B27","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"23","key":"2026050604165853000_bqag035-B28","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2026050604165853000_bqag035-B29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126522","article-title":"Stemness of the hybrid epithelial\/mesenchymal state in breast cancer and its association with poor survival","volume":"10","author":"Grosse-Wilde","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"2026050604165853000_bqag035-B30","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.3324\/haematol.2019.226282","article-title":"Plasticity in growth behavior of patients\u2019 acute myeloid leukemia stem cells growing in mice","volume":"105","author":"Ebinger","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"2026050604165853000_bqag035-B31","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1158\/2159-8290.CD-23-0225","article-title":"The transcriptional and epigenetic landscape of cancer cell lineage plasticity","volume":"13","author":"Davies","year":"2023","journal-title":"Cancer Discov"},{"issue":"2","key":"2026050604165853000_bqag035-B32","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1002\/mco2.144","article-title":"Epithelial-mesenchymal transition: the history, regulatory mechanism, and cancer therapeutic opportunities","volume":"3","author":"Huang","year":"2022","journal-title":"MedComm (2020)"},{"issue":"40","key":"2026050604165853000_bqag035-B33","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2406837121","article-title":"A molecular switch from tumor suppressor to oncogene in ER+ve breast cancer: role of androgen receptor, JAK-STAT, and lineage plasticity","volume":"121","author":"Asemota","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8095","key":"2026050604165853000_bqag035-B34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41586-025-09727-z","article-title":"NSD2 targeting reverses plasticity and drug resistance in prostate cancer","volume":"649","author":"Li","year":"2026","journal-title":"Nature"},{"issue":"12","key":"2026050604165853000_bqag035-B35","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113461","article-title":"Identification of a targetable JAK-STAT enriched androgen receptor and androgen receptor splice variant positive triple-negative breast cancer subtype","volume":"42","author":"Asemota","year":"2023","journal-title":"Cell Rep"},{"issue":"9","key":"2026050604165853000_bqag035-B36","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s43018-022-00431-9","article-title":"Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance","volume":"3","author":"Deng","year":"2022","journal-title":"Nat Cancer"},{"issue":"6611","key":"2026050604165853000_bqag035-B37","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1126\/science.abn0478","article-title":"Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling","volume":"377","author":"Chan","year":"2022","journal-title":"Science"},{"issue":"5240","key":"2026050604165853000_bqag035-B38","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1126\/science.270.5240.1354","article-title":"Sequence and characterization of a coactivator for the steroid hormone receptor superfamily","volume":"270","author":"Onate","year":"1995","journal-title":"Science"},{"issue":"1","key":"2026050604165853000_bqag035-B39","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/MCB.25.1.264-277.2005","article-title":"Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A\/Cdk2 as a progesterone receptor coactivator","volume":"25","author":"Narayanan","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"11","key":"2026050604165853000_bqag035-B40","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1039\/B606246F","article-title":"Structure, function, and regulation of STAT proteins","volume":"2","author":"Lim","year":"2006","journal-title":"Mol Biosyst"},{"issue":"19","key":"2026050604165853000_bqag035-B41","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1128\/MCB.20.19.7132-7139.2000","article-title":"The coiled-coil domain of Stat3 is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6","volume":"20","author":"Zhang","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"1","key":"2026050604165853000_bqag035-B42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1074-7613(00)80505-1","article-title":"Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet?","volume":"7","author":"O'Shea","year":"1997","journal-title":"Immunity"},{"issue":"5","key":"2026050604165853000_bqag035-B43","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1073\/pnas.86.5.1603","article-title":"Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction","volume":"86","author":"Wilks","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"2026050604165853000_bqag035-B44","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0024-3205(98)00538-4","article-title":"Janus kinases and their role in growth and disease","volume":"64","author":"Aringer","year":"1999","journal-title":"Life Sci"},{"issue":"1-4","key":"2026050604165853000_bqag035-B45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10799899909036638","article-title":"The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus","volume":"19","author":"Heim","year":"1999","journal-title":"J Recept Signal Transduct Res"},{"issue":"14","key":"2026050604165853000_bqag035-B46","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1073\/pnas.91.14.6374","article-title":"Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes","volume":"91","author":"Kawamura","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026050604165853000_bqag035-B47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"2026050604165853000_bqag035-B48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0952-7915(98)80165-9","article-title":"JAK\/STAT signaling by cytokine receptors","volume":"10","author":"Liu","year":"1998","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"2026050604165853000_bqag035-B49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/ar66","article-title":"Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation","volume":"2","author":"Ortmann","year":"2000","journal-title":"Arthritis Res"},{"issue":"8","key":"2026050604165853000_bqag035-B50","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nsmb.2348","article-title":"Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F","volume":"19","author":"Bandaranayake","year":"2012","journal-title":"Nat Struct Mol Biol"},{"issue":"6589","key":"2026050604165853000_bqag035-B51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1126\/science.abn8933","article-title":"Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation","volume":"376","author":"Glassman","year":"2022","journal-title":"Science"},{"issue":"6185","key":"2026050604165853000_bqag035-B52","doi-asserted-by":"crossref","DOI":"10.1126\/science.1249783","article-title":"Mechanism of activation of protein kinase JAK2 by the growth hormone receptor","volume":"344","author":"Brooks","year":"2014","journal-title":"Science"},{"issue":"5","key":"2026050604165853000_bqag035-B53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156218","article-title":"Crystal structure of the FERM-SH2 module of human Jak2","volume":"11","author":"McNally","year":"2016","journal-title":"PLoS One"},{"issue":"22","key":"2026050604165853000_bqag035-B54","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1073\/pnas.1401180111","article-title":"Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition","volume":"111","author":"Lupardus","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2026050604165853000_bqag035-B55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nsmb.2807","article-title":"Structural basis of recognition of interferon-alpha receptor by tyrosine kinase 2","volume":"21","author":"Wallweber","year":"2014","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"2026050604165853000_bqag035-B56","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jsb.2012.12.009","article-title":"Structure-guided studies of the SHP-1\/JAK1 interaction provide new insights into phosphatase catalytic domain substrate recognition","volume":"181","author":"Alicea-Velazquez","year":"2013","journal-title":"J Struct Biol"},{"issue":"1","key":"2026050604165853000_bqag035-B57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1083\/jcb.200703184","article-title":"JAK1-STAT1-STAT3, a key pathway promoting proliferation and preventing premature differentiation of myoblasts","volume":"179","author":"Sun","year":"2007","journal-title":"J Cell Biol"},{"issue":"6455","key":"2026050604165853000_bqag035-B58","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/366583a0","article-title":"Interferon-induced nuclear signalling by Jak protein tyrosine kinases","volume":"366","author":"Silvennoinen","year":"1993","journal-title":"Nature"},{"issue":"18","key":"2026050604165853000_bqag035-B59","doi-asserted-by":"crossref","first-page":"8429","DOI":"10.1073\/pnas.90.18.8429","article-title":"Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction","volume":"90","author":"Silvennoinen","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6451","key":"2026050604165853000_bqag035-B60","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/366166a0","article-title":"Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway","volume":"366","author":"Watling","year":"1993","journal-title":"Nature"},{"issue":"6485","key":"2026050604165853000_bqag035-B61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/370151a0","article-title":"Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2","volume":"370","author":"Johnston","year":"1994","journal-title":"Nature"},{"issue":"5573","key":"2026050604165853000_bqag035-B62","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1126\/science.1071545","article-title":"A road map for those who don't know JAK-STAT","volume":"296","author":"Aaronson","year":"2002","journal-title":"Science"},{"issue":"5","key":"2026050604165853000_bqag035-B63","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0092-8674(00)81443-9","article-title":"Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA","volume":"93","author":"Chen","year":"1998","journal-title":"Cell"},{"issue":"9","key":"2026050604165853000_bqag035-B64","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6024","key":"2026050604165853000_bqag035-B65","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.1203543","article-title":"A perspective on cancer cell metastasis","volume":"331","author":"Chaffer","year":"2011","journal-title":"Science"},{"issue":"7","key":"2026050604165853000_bqag035-B66","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10875-016-0312-3","article-title":"Severe early-onset combined immunodeficiency due to heterozygous gain-of-function mutations in STAT1","volume":"36","author":"Baris","year":"2016","journal-title":"J Clin Immunol"},{"issue":"1","key":"2026050604165853000_bqag035-B67","article-title":"STAT2: a shape-shifting anti-viral super STAT","volume":"2","author":"Chowdhury","year":"2013","journal-title":"JAKSTAT"},{"issue":"10","key":"2026050604165853000_bqag035-B68","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI0215770","article-title":"IFNs and STATs in innate immunity to microorganisms","volume":"109","author":"Decker","year":"2002","journal-title":"J Clin Invest"},{"issue":"2","key":"2026050604165853000_bqag035-B69","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41568-018-0090-8","article-title":"Therapeutically exploiting STAT3 activity in cancer\u2014using tissue repair as a road map","volume":"19","author":"Huynh","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"2026050604165853000_bqag035-B70","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141326","article-title":"STAT4 is expressed in neutrophils and promotes antimicrobial immunity","volume":"6","author":"Mehrpouya-Bahrami","year":"2021","journal-title":"JCI Insight"},{"issue":"4","key":"2026050604165853000_bqag035-B71","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1074\/jbc.274.4.1875","article-title":"Identification of a STAT4 binding site in the interleukin-12 receptor required for signaling","volume":"274","author":"Naeger","year":"1999","journal-title":"J Biol Chem"},{"issue":"6","key":"2026050604165853000_bqag035-B72","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1074-7613(00)00077-7","article-title":"Immune response in Stat2 knockout mice","volume":"13","author":"Park","year":"2000","journal-title":"Immunity"},{"issue":"1","key":"2026050604165853000_bqag035-B73","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: a complex web of host defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"2026050604165853000_bqag035-B74","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.7150\/ijbs.41852","article-title":"STAT4: an immunoregulator contributing to diverse human diseases","volume":"16","author":"Yang","year":"2020","journal-title":"Int J Biol Sci"},{"issue":"2","key":"2026050604165853000_bqag035-B75","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc1275","article-title":"The STATs of cancer\u2013new molecular targets come of age","volume":"4","author":"Yu","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2026050604165853000_bqag035-B76","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12026-011-8205-2","article-title":"Transcriptional regulation by STAT6","volume":"50","author":"Goenka","year":"2011","journal-title":"Immunol Res"},{"key":"2026050604165853000_bqag035-B77","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153477","article-title":"STAT6: a review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology","volume":"223","author":"Karpathiou","year":"2021","journal-title":"Pathol Res Pract"},{"issue":"2","key":"2026050604165853000_bqag035-B78","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1359-6101(99)00011-8","article-title":"Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation","volume":"10","author":"Grimley","year":"1999","journal-title":"Cytokine Growth Factor Rev"},{"issue":"14","key":"2026050604165853000_bqag035-B79","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1096\/fasebj.10.14.9002549","article-title":"Regulation of STAT-dependent pathways by growth factors and cytokines","volume":"10","author":"Leaman","year":"1996","journal-title":"FASEB J"},{"issue":"17","key":"2026050604165853000_bqag035-B80","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1093\/emboj\/18.17.4754","article-title":"STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells","volume":"18","author":"Nosaka","year":"1999","journal-title":"EMBO J"},{"issue":"1","key":"2026050604165853000_bqag035-B81","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41392-025-02340-6","article-title":"Epigenetic regulation of cancer stemness","volume":"10","author":"Galassi","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2026050604165853000_bqag035-B82","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0117-x","article-title":"Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer","volume":"32","author":"Wingelhofer","year":"2018","journal-title":"Leukemia"},{"issue":"10074","key":"2026050604165853000_bqag035-B83","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"2026050604165853000_bqag035-B84","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"6797","key":"2026050604165853000_bqag035-B85","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"1","key":"2026050604165853000_bqag035-B86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3892\/br.2013.187","article-title":"Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (review)","volume":"2","author":"Zhang","year":"2014","journal-title":"Biomed Rep"},{"issue":"1","key":"2026050604165853000_bqag035-B87","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/00313020802563510","article-title":"Triple-negative\/basal-like breast cancer: review","volume":"41","author":"Rakha","year":"2009","journal-title":"Pathology"},{"key":"2026050604165853000_bqag035-B88","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120996","article-title":"Role of STAT3 in the initiation, progression, proliferation and metastasis of breast cancer and strategies to deliver JAK and STAT3 inhibitors","volume":"309","author":"Dinakar","year":"2022","journal-title":"Life Sci"},{"issue":"1","key":"2026050604165853000_bqag035-B89","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume":"22","author":"Ye","year":"2023","journal-title":"Mol Cancer"},{"issue":"17","key":"2026050604165853000_bqag035-B90","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1158\/1078-0432.CCR-19-4191","article-title":"Activation of the IFN signaling pathway is associated with resistance to CDK4\/6 inhibitors and immune checkpoint activation in ER-positive breast cancer","volume":"27","author":"De Angelis","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"Pt 3","key":"2026050604165853000_bqag035-B91","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.semcancer.2022.08.003","article-title":"STAT family of transcription factors in breast cancer: pathogenesis and therapeutic opportunities and challenges","volume":"86","author":"Wong","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"2026050604165853000_bqag035-B92","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3390\/cancers17111781","article-title":"The roles of STAT3 and STAT5 in breast cancer","volume":"17","author":"Temple","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2026050604165853000_bqag035-B93","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"2026050604165853000_bqag035-B94","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/cancers14020429","article-title":"STAT3 signaling in breast cancer: multicellular actions and therapeutic potential","volume":"14","author":"To","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026050604165853000_bqag035-B95","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.isci.2019.10.038","article-title":"Androgen receptor is a non-canonical inhibitor of wild-type and mutant estrogen receptors in hormone receptor-positive breast cancers","volume":"21","author":"Ponnusamy","year":"2019","journal-title":"iScience"},{"issue":"19","key":"2026050604165853000_bqag035-B96","doi-asserted-by":"crossref","first-page":"14777","DOI":"10.3390\/ijms241914777","article-title":"Modulation of JAK-STAT signaling by LNK: a forgotten oncogenic pathway in hormone receptor-positive breast cancer","volume":"24","author":"L\u00f3pez-Mej\u00eda","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2026050604165853000_bqag035-B97","doi-asserted-by":"crossref","first-page":"416","DOI":"10.14740\/jocmr4785","article-title":"STAT-5 and STAT-6 in breast cancer: potential crosstalk with estrogen and progesterone receptors can affect cell proliferation and metastasis","volume":"14","author":"Oueslati","year":"2022","journal-title":"J Clin Med Res"},{"issue":"3","key":"2026050604165853000_bqag035-B98","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ccell.2020.06.007","article-title":"IL6\/STAT3 signaling hijacks estrogen receptor alpha enhancers to drive breast cancer metastasis","volume":"38","author":"Siersbaek","year":"2020","journal-title":"Cancer Cell"},{"issue":"19","key":"2026050604165853000_bqag035-B99","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2026050604165853000_bqag035-B100","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3892\/ijo.2013.2195","article-title":"STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits","volume":"44","author":"Chung","year":"2014","journal-title":"Int J Oncol"},{"issue":"35","key":"2026050604165853000_bqag035-B101","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1038\/onc.2015.527","article-title":"WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2\/HER3 signaling","volume":"35","author":"Teng","year":"2016","journal-title":"Oncogene"},{"issue":"13","key":"2026050604165853000_bqag035-B102","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1158\/0008-5472.CAN-11-0308","article-title":"HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis","volume":"71","author":"Hartman","year":"2011","journal-title":"Cancer Res"},{"issue":"3","key":"2026050604165853000_bqag035-B103","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"2026050604165853000_bqag035-B104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"2026050604165853000_bqag035-B105","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"issue":"1","key":"2026050604165853000_bqag035-B106","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13578-025-01359-0","article-title":"Classifications of triple-negative breast cancer: insights and current therapeutic approaches","volume":"15","author":"Chen","year":"2025","journal-title":"Cell Biosci"},{"issue":"1","key":"2026050604165853000_bqag035-B107","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13046-019-1206-z","article-title":"STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review","volume":"38","author":"Qin","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"334","key":"2026050604165853000_bqag035-B108","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad3001","article-title":"Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence","volume":"8","author":"Balko","year":"2016","journal-title":"Sci Transl Med"},{"issue":"1","key":"2026050604165853000_bqag035-B109","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2211832120","article-title":"Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer","volume":"120","author":"Thiyagarajan","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"2026050604165853000_bqag035-B110","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-17-0976","article-title":"Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer","volume":"77","author":"Ponnusamy","year":"2017","journal-title":"Cancer Res"},{"issue":"22","key":"2026050604165853000_bqag035-B111","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-19-1458","article-title":"Orally bioavailable androgen receptor degrader, potential next-generation therapeutic for enzalutamide-resistant prostate cancer","volume":"25","author":"Ponnusamy","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026050604165853000_bqag035-B112","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"2026050604165853000_bqag035-B113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139440","article-title":"Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model","volume":"10","author":"Scher","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"2026050604165853000_bqag035-B114","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/path.1711600409","article-title":"Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry","volume":"160","author":"de Winter","year":"1990","journal-title":"J Pathol"},{"issue":"12","key":"2026050604165853000_bqag035-B115","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.3390\/cells9122653","article-title":"Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications","volume":"9","author":"Aurilio","year":"2020","journal-title":"Cells"},{"key":"2026050604165853000_bqag035-B116","first-page":"211","article-title":"Androgen receptor signalling in prostate cancer: mechanisms of resistance to endocrine therapies","volume":"17","author":"Quistini","year":"2025","journal-title":"Res Rep Urol"},{"issue":"1","key":"2026050604165853000_bqag035-B117","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2548975","article-title":"Mechanisms of neuroendocrine differentiation in castration-resistant prostate cancer and advances in the treatment of neuroendocrine prostate cancer","volume":"57","author":"Shao","year":"2025","journal-title":"Ann Med"},{"issue":"4","key":"2026050604165853000_bqag035-B118","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.2353\/ajpath.2010.090653","article-title":"Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth","volume":"176","author":"Gu","year":"2010","journal-title":"Am J Pathol"},{"issue":"49","key":"2026050604165853000_bqag035-B119","doi-asserted-by":"crossref","first-page":"85997","DOI":"10.18632\/oncotarget.20844","article-title":"STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer","volume":"8","author":"Mohanty","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2026050604165853000_bqag035-B120","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41420-020-0272-5","article-title":"Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells","volume":"6","author":"Cheteh","year":"2020","journal-title":"Cell Death Discov"},{"issue":"2","key":"2026050604165853000_bqag035-B121","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/cancers6020829","article-title":"The multifaceted roles of STAT3 signaling in the progression of prostate cancer","volume":"6","author":"Bishop","year":"2014","journal-title":"Cancers (Basel)"},{"key":"2026050604165853000_bqag035-B122","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155558","article-title":"Dysregulated expression of the suppressors of cytokine signaling (SOCS) contributes to the development of prostate cancer","volume":"262","author":"Jafarzadeh","year":"2024","journal-title":"Pathol Res Pract"},{"issue":"9","key":"2026050604165853000_bqag035-B123","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adi2742","article-title":"Stat5 induces androgen receptor (AR) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling","volume":"10","author":"Maranto","year":"2024","journal-title":"Sci Adv"},{"issue":"4","key":"2026050604165853000_bqag035-B124","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/0008-5472.CAN-13-0594","article-title":"Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling","volume":"74","author":"Schroeder","year":"2014","journal-title":"Cancer Res"},{"issue":"4","key":"2026050604165853000_bqag035-B125","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqad023","article-title":"Beyond expression: role of phosphorylated residues of EZH2 in lineage plasticity in prostate cancer","volume":"164","author":"Nouruzi","year":"2023","journal-title":"Endocrinology"},{"issue":"11","key":"2026050604165853000_bqag035-B126","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168649","article-title":"Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs","volume":"134","author":"Han","year":"2024","journal-title":"J Clin Invest"},{"issue":"12","key":"2026050604165853000_bqag035-B127","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1038\/s41588-024-01979-1","article-title":"JAK\/STAT signaling maintains an intermediate cell population during prostate basal cell fate determination","volume":"56","author":"Guo","year":"2024","journal-title":"Nat Genet"},{"issue":"2","key":"2026050604165853000_bqag035-B128","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/cancers16020392","article-title":"ID2 promotes lineage transition of prostate cancer through FGFR and JAK-STAT signaling","volume":"16","author":"Zhang","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2026050604165853000_bqag035-B129","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026050604165853000_bqag035-B130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-023-01471-z","article-title":"Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety","volume":"16","author":"Verstovsek","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2026050604165853000_bqag035-B131","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"2026050604165853000_bqag035-B132","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2026050604165853000_bqag035-B133","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41409-024-02252-z","article-title":"Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis","volume":"59","author":"Baccelli","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2026050604165853000_bqag035-B134","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4103\/aja.aja_41_18","article-title":"Lineage plasticity-mediated therapy resistance in prostate cancer","volume":"21","author":"Blee","year":"2019","journal-title":"Asian J Androl"},{"issue":"5_suppl","key":"2026050604165853000_bqag035-B135","doi-asserted-by":"crossref","first-page":"TPS297","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS297","article-title":"Study of JAK inhibition in stem-like prostate cancer (JASPER): a phase 1\/2 multicenter study of ruxolitinib and enzalutamide in castration resistant prostate cancer undergoing lineage plasticity","volume":"43","author":"Westbrook","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026050604165853000_bqag035-B136","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-22-0423","article-title":"JAK-STAT signaling in inflammatory breast cancer enables chemotherapy-resistant cell states","volume":"83","author":"Stevens","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"2026050604165853000_bqag035-B137","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13058-024-01774-0","article-title":"TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer","volume":"26","author":"Lynce","year":"2024","journal-title":"Breast Cancer Res"},{"issue":"13","key":"2026050604165853000_bqag035-B138","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2026050604165853000_bqag035-B139","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1080\/09546634.2021.1967268","article-title":"Baricitinib for the treatment of atopic dermatitis","volume":"33","author":"Melo","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"2026050604165853000_bqag035-B140","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jdv.19768","article-title":"European expert consensus statement on the systemic treatment of alopecia areata","volume":"38","author":"Rudnicka","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"20","key":"2026050604165853000_bqag035-B141","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.3390\/cancers13205204","article-title":"Second-generation Jak2 inhibitors for advanced prostate cancer: are we ready for clinical development?","volume":"13","author":"Beinhoff","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026050604165853000_bqag035-B142","first-page":"318","article-title":"The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"2026050604165853000_bqag035-B143","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"2026050604165853000_bqag035-B144","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s40265-022-01718-y","article-title":"Pacritinib: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"issue":"23","key":"2026050604165853000_bqag035-B145","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2026050604165853000_bqag035-B146","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"2026050604165853000_bqag035-B147","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/jdv.19162","article-title":"Topical ruxolitinib: a new treatment for vitiligo","volume":"37","author":"Tavoletti","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"15","key":"2026050604165853000_bqag035-B148","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40265-019-01205-x","article-title":"Fedratinib: first approval","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"2026050604165853000_bqag035-B149","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"Fedratinib","year":"2012"},{"issue":"5","key":"2026050604165853000_bqag035-B150","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"5","key":"2026050604165853000_bqag035-B151","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"issue":"19","key":"2026050604165853000_bqag035-B152","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"7","author":"Oh","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"2026050604165853000_bqag035-B153","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1358\/dot.2022.58.12.3474538","article-title":"Pacritinib for myelofibrosis in adults with thrombocytopenia","volume":"58","author":"Yang","year":"2022","journal-title":"Drugs Today (Barc)"},{"issue":"18","key":"2026050604165853000_bqag035-B154","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s40265-023-01964-8","article-title":"Momelotinib: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"2026050604165853000_bqag035-B155","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","article-title":"Momelotinib: an emerging treatment for myelofibrosis patients with anemia","volume":"15","author":"Chifotides","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2026050604165853000_bqag035-B156","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2023023719","article-title":"Momelotinib for the treatment of myelofibrosis","volume":"144","author":"Bose","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2026050604165853000_bqag035-B157","doi-asserted-by":"crossref","first-page":"400","DOI":"10.23736\/S0392-0488.20.06643-2","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"155","author":"Ighani","year":"2020","journal-title":"G Ital Dermatol Venereol"},{"issue":"14","key":"2026050604165853000_bqag035-B158","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2217\/imt-2017-0087","article-title":"Tofacitinib in psoriatic arthritis","volume":"9","author":"Wang","year":"2017","journal-title":"Immunotherapy"},{"issue":"7","key":"2026050604165853000_bqag035-B159","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"10315","key":"2026050604165853000_bqag035-B160","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2026050604165853000_bqag035-B161","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"1","key":"2026050604165853000_bqag035-B162","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13075-024-03358-x","article-title":"Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial","volume":"26","author":"van Vollenhoven","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2026050604165853000_bqag035-B163","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2022-11-6","article-title":"Upadacitinib for the treatment of psoriatic arthritis","volume":"12","author":"Fonseca","year":"2023","journal-title":"Drugs Context"},{"issue":"1","key":"2026050604165853000_bqag035-B164","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"issue":"10246","key":"2026050604165853000_bqag035-B165","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"2026050604165853000_bqag035-B166","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/1744666X.2023.2149495","article-title":"Filgotinib in rheumatoid arthritis","volume":"19","author":"Westhovens","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"2026050604165853000_bqag035-B167","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/imt-2023-0116","article-title":"The role of filgotinib in ulcerative colitis and Crohn's disease","volume":"16","author":"Fanizza","year":"2024","journal-title":"Immunotherapy"},{"issue":"2","key":"2026050604165853000_bqag035-B168","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","article-title":"Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program","volume":"25","author":"King","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"14","key":"2026050604165853000_bqag035-B169","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40265-023-01928-y","article-title":"Ritlecitinib: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"issue":"5","key":"2026050604165853000_bqag035-B170","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1)","volume":"91","author":"King","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2026050604165853000_bqag035-B171","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1756-8722-6-90","article-title":"STAT inhibitors for cancer therapy","volume":"6","author":"Furqan","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2026050604165853000_bqag035-B172","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/cancers12010024","article-title":"Activation of STAT3 and STAT5 signaling in epithelial ovarian cancer progression: mechanism and therapeutic opportunity","volume":"12","author":"Wu","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"18","key":"2026050604165853000_bqag035-B173","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/0008-5472.CAN-15-1122","article-title":"STAT3 inhibition enhances the therapeutic efficacy of immunogenic chemotherapy by stimulating type 1 interferon production by cancer cells","volume":"75","author":"Yang","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"2026050604165853000_bqag035-B174","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/cancers12010019","article-title":"STAT3 activation and oncogenesis in lymphoma","volume":"12","author":"Zhu","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2026050604165853000_bqag035-B175","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/cam4.675","article-title":"Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin","volume":"5","author":"Zhang","year":"2016","journal-title":"Cancer Med"},{"issue":"15","key":"2026050604165853000_bqag035-B176","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.3390\/molecules28155678","article-title":"The anticancer effect of napabucasin (BBI608), a natural naphthoquinone","volume":"28","author":"Shao","year":"2023","journal-title":"Molecules"},{"issue":"12","key":"2026050604165853000_bqag035-B177","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2217\/fon-2018-0903","article-title":"CanStem111P trial: a phase III study of napabucasin plus nab-paclitaxel with gemcitabine","volume":"15","author":"Sonbol","year":"2019","journal-title":"Future Oncol"},{"issue":"1","key":"2026050604165853000_bqag035-B178","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00280-025-04770-z","article-title":"Napabucasin targets resistant triple negative breast cancer through suppressing STAT3 and mitochondrial function","volume":"95","author":"Yuan","year":"2025","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"2026050604165853000_bqag035-B179","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2006.09.018","article-title":"Stattic: a small-molecule inhibitor of STAT3 activation and dimerization","volume":"13","author":"Schust","year":"2006","journal-title":"Chem Biol"},{"issue":"1","key":"2026050604165853000_bqag035-B180","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41420-022-00922-9","article-title":"Inhibition of STAT3(Y705) phosphorylation by Stattic suppresses proliferation and induces mitochondrial-dependent apoptosis in pancreatic cancer cells","volume":"8","author":"Guo","year":"2022","journal-title":"Cell Death Discov"},{"key":"2026050604165853000_bqag035-B181","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.016645","article-title":"The STAT3 inhibitor Stattic acts independently of STAT3 to decrease histone acetylation and modulate gene expression","volume":"296","author":"Poria","year":"2021","journal-title":"J Biol Chem"},{"issue":"8","key":"2026050604165853000_bqag035-B182","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/CAD.0000000000000783","article-title":"C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma","volume":"30","author":"Di","year":"2019","journal-title":"Anticancer Drugs"},{"key":"2026050604165853000_bqag035-B183","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114688","article-title":"TTI-101: a competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain","volume":"192","author":"Kasembeli","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"2026050604165853000_bqag035-B184","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1158\/1078-0432.CCR-24-2920","article-title":"Phase I trial of TTI-101, a first-in-class oral inhibitor of STAT3, in patients with advanced solid tumors","volume":"31","author":"Tsimberidou","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026050604165853000_bqag035-B185","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12935-024-03463-6","article-title":"TTI-101 targets STAT3\/c-Myc signaling pathway to suppress cervical cancer progression: an integrated experimental and computational analysis","volume":"24","author":"Li","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"17","key":"2026050604165853000_bqag035-B186","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2174\/1871520619666190906160848","article-title":"STAT5 and STAT5 inhibitors in hematological malignancies","volume":"19","author":"Tolomeo","year":"2019","journal-title":"Anticancer Agents Med Chem"},{"issue":"23","key":"2026050604165853000_bqag035-B187","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1158\/0008-5472.CAN-22-1293","article-title":"Targeting STAT5 signaling overcomes resistance to IDH inhibitors in acute myeloid leukemia through suppression of stemness","volume":"82","author":"Liu","year":"2022","journal-title":"Cancer Res"},{"issue":"11","key":"2026050604165853000_bqag035-B188","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.3390\/cancers12113412","article-title":"Prospects for clinical development of Stat5 inhibitor IST5-002: high transcriptomic specificity in prostate cancer and low toxicity in vivo","volume":"12","author":"Maranto","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2026050604165853000_bqag035-B189","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.3390\/cancers12082002","article-title":"Targeting STAT3 and STAT5 in cancer","volume":"12","author":"de Araujo","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026050604165853000_bqag035-B190","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1677\/ERC-09-0328","article-title":"Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo","volume":"17","author":"Gu","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"2026050604165853000_bqag035-B191","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237248","article-title":"Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer","volume":"15","author":"Erb","year":"2020","journal-title":"PLoS One"},{"issue":"52","key":"2026050604165853000_bqag035-B192","doi-asserted-by":"crossref","first-page":"22617","DOI":"10.1073\/pnas.1009152108","article-title":"IL-4\/STAT6 immune axis regulates peripheral nutrient metabolism and insulin sensitivity","volume":"107","author":"Ricardo-Gonzalez","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"2026050604165853000_bqag035-B193","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.3390\/ijms21155382","article-title":"Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis","volume":"21","author":"Furue","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2026050604165853000_bqag035-B194","article-title":"Learning while treating: gain-of-function STAT6 variants in severe allergic disease","volume":"4","author":"Smith","year":"2023","journal-title":"Cell Rep Med"},{"issue":"2","key":"2026050604165853000_bqag035-B195","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaci.2022.09.028","article-title":"A germline STAT6 gain-of-function variant is associated with early-onset allergies","volume":"151","author":"Suratannon","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"2026050604165853000_bqag035-B196","doi-asserted-by":"crossref","first-page":"6556","DOI":"10.1074\/jbc.272.10.6556","article-title":"Jak1 expression is required for mediating interleukin-4-induced tyrosine phosphorylation of insulin receptor substrate and Stat6 signaling molecules","volume":"272","author":"Chen","year":"1997","journal-title":"J Biol Chem"},{"issue":"13","key":"2026050604165853000_bqag035-B197","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.3390\/ijms22136995","article-title":"Macrophage polarization states in the tumor microenvironment","volume":"22","author":"Boutilier","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2026050604165853000_bqag035-B198","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3390\/biom12030447","article-title":"Inhibition of STAT6 activation by AS1517499 inhibits expression and activity of PPAR\u03b3 in macrophages to resolve acute inflammation in mice","volume":"12","author":"Lee","year":"2022","journal-title":"Biomolecules"},{"key":"2026050604165853000_bqag035-B199","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102494","article-title":"NR4A3high mast cells promote ovarian cancer metastasis by reprogramming tumor-associated macrophages via JAK2\/STAT6 signaling","volume":"60","author":"Bian","year":"2025","journal-title":"Transl Oncol"},{"issue":"2","key":"2026050604165853000_bqag035-B200","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1096\/fj.201700629R","article-title":"Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer","volume":"32","author":"Binnemars-Postma","year":"2018","journal-title":"FASEB J"},{"issue":"4","key":"2026050604165853000_bqag035-B201","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 15","key":"2026050604165853000_bqag035-B202","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.2016.34.15_suppl.1094","article-title":"A phase Ib\/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced triple negative breast cancer","volume":"34","author":"Becerra","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026050604165853000_bqag035-B203","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.2530","volume-title":"A Phase 1b Study of the Cancer Stem Cell Inhibitor BBI608 Administered with Paclitaxel in Patients with Advanced Malignancies","author":"Hitron","year":"2014"},{"issue":"1","key":"2026050604165853000_bqag035-B204","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10549-021-06306-4","article-title":"Phase I\/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer","volume":"189","author":"Kearney","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2026050604165853000_bqag035-B205","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41523-022-00487-x","article-title":"Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer","volume":"8","author":"Makhlin","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"2026050604165853000_bqag035-B206","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00280-021-04245-x","article-title":"Phase I study of JAK1\/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer","volume":"87","author":"Lynce","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2026050604165853000_bqag035-B207","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41523-018-0060-z","article-title":"Phase II study of ruxolitinib, a selective JAK1\/2 inhibitor, in patients with metastatic triple-negative breast cancer","volume":"4","author":"Stover","year":"2018","journal-title":"NPJ Breast Cancer"},{"issue":"9_Supplement","key":"2026050604165853000_bqag035-B208","doi-asserted-by":"crossref","first-page":"PO1","DOI":"10.1158\/1538-7445.SABCS23-PO1-18-07","article-title":"Abstract PO1-18-07: phase I trial of combination pembrolizumab and ruxolitinib in metastatic triple negative breast cancer","volume":"84","author":"Kassi","year":"2024","journal-title":"Cancer Res"},{"key":"2026050604165853000_bqag035-B209","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cytogfr.2025.01.003","article-title":"Insights into IL-6\/JAK\/STAT3 signaling in the tumor microenvironment: implications for cancer therapy","volume":"85","author":"Thuya","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"issue":"11","key":"2026050604165853000_bqag035-B210","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2026050604165853000_bqag035-B211","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2026050604165853000_bqag035-B212","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s12935-024-03541-9","article-title":"STAT3: key targets of growth-promoting receptor positive breast cancer","volume":"24","author":"Jiang","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"19","key":"2026050604165853000_bqag035-B213","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.3390\/cancers13194854","article-title":"Impact of STAT proteins in tumor progress and therapy resistance in advanced and metastasized prostate cancer","volume":"13","author":"Ebersbach","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"15","key":"2026050604165853000_bqag035-B214","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1101\/gad.262642.115","article-title":"Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-\/HER2+ breast cancers","volume":"29","author":"Rodriguez-Barrueco","year":"2015","journal-title":"Genes Dev"},{"issue":"25","key":"2026050604165853000_bqag035-B215","doi-asserted-by":"crossref","first-page":"12442","DOI":"10.1073\/pnas.1816410116","article-title":"JAK\/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors","volume":"116","author":"Irey","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2026050604165853000_bqag035-B216","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.3390\/cancers11121832","article-title":"Targeting STAT3 and STAT5 in tumor-associated immune cells to improve immunotherapy","volume":"11","author":"Verdeil","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026050604165853000_bqag035-B217","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/cells15010025","article-title":"Inhibition of tumor microenvironment-driven JAK-STAT signaling enhances response to arginine deprivation therapy in triple-negative breast cancer","volume":"15","author":"Tishler","year":"2026","journal-title":"Cells"},{"issue":"1","key":"2026050604165853000_bqag035-B218","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2026050604165853000_bqag035-B219","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1021\/acs.jcim.2c01589","article-title":"Selectivity and ranking of tight-binding JAK-STAT inhibitors using Markovian milestoning with Voronoi tessellations","volume":"63","author":"Ojha","year":"2023","journal-title":"J Chem Inf Model"},{"issue":"4","key":"2026050604165853000_bqag035-B220","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"key":"2026050604165853000_bqag035-B221","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1459777","article-title":"Combination of JAK inhibitor and immune checkpoint inhibitor in clinical trials: a breakthrough","volume":"15","author":"Dong","year":"2024","journal-title":"Front Immunol"},{"key":"2026050604165853000_bqag035-B222","article-title":"Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy","volume":"14","author":"Wei","year":"2023","journal-title":"Front Pharmacol"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqag035\/67640221\/bqag035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/5\/bqag035\/67640221\/bqag035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/5\/bqag035\/67640221\/bqag035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:18:06Z","timestamp":1778055486000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqag035\/8556299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":222,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,7]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqag035","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,3,30]]},"article-number":"bqag035"}}